Heart problems linked to cancer immunotherapy drugs
Part of Heart & circulation clinical trials.
This study looks at reports from large health databases to find out if certain cancer drugs (checkpoint inhibitors) cause heart problems. It aims to understand which patients have a higher risk, which may help doctors watch for heart issues in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were treated with one of these cancer drugs: ipilimumab, nivolumab, pembrolizumab, durvalumab, avelumab, atezolizumab, or cemiplimab.
- You had a heart-related side effect, such as a heart attack, rhythm problem, or heart failure, that might be linked to the treatment.
- Your case is in one of the health databases: the World Health Organization database, a French hospital database, the French national health database, or an international registry for a type of heart muscle inflammation caused by these drugs.
- The timing of your heart problem seems related to when you received the drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether immunotherapy drugs (checkpoint inhibitors) cause heart problems in people with certain cancers. It will help doctors understand who is at risk and how to monitor for side effects.
This study is a “registry,” meaning it collects health information from adults who are getting a new heart (cardio) evaluation related to cancer. It helps doctors better understand heart risks and care needs for different cancer types and treatments.
This study looks at genetic factors that may affect the risk of heart inflammation (myocarditis) caused by immune checkpoint inhibitors (ICIs), a type of cancer immunotherapy. It aims to find out if your genes make you more likely to develop this side effect.
This research tracks outcomes for cancer patients who developed heart inflammation (myocarditis) while receiving immune checkpoint inhibitor therapy. By studying survival patterns, researchers hope to better understand how to manage this serious side effect and improve care for future patients.
This study looks at blood vessel problems that may happen when people take immunotherapy (a type of cancer treatment that helps your immune system fight cancer). If you join, doctors will watch for these side effects and learn more about how to manage them.
This trial looks at a faster heart and blood-vessel assessment for people who are taking immune cancer drugs and have been referred because they might be having a heart-related side effect. It may help by speeding up evaluation and treatment decisions when symptoms raise concern.
Hear when a new Myocarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.